Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)Business Wire • 08/16/21
Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11Business Wire • 08/04/21
Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle ConferenceBusiness Wire • 06/22/21
Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceBusiness Wire • 06/01/21
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent HighlightsBusiness Wire • 05/13/21
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular DystrophyBusiness Wire • 05/04/21
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical OfficerBusiness Wire • 04/27/21
Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 03/30/21